Anti-PD-1-Induced Hidradenitis Suppurativa

Mucocutaneous adverse events are commonly observed under immune checkpoint inhibitors (ICIs) therapy. Here, we report the case of a 43-year-old male patient with a stage IIIC melanoma disease who developed hidradenitis suppurativa (HS) three months after the beginning of an anti-PD-1 (nivolumab) adj...

Descripción completa

Detalles Bibliográficos
Autores principales: Maillard, Alexia, Pastor, Damien, Merat, Rastine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008319/
https://www.ncbi.nlm.nih.gov/pubmed/33668724
http://dx.doi.org/10.3390/dermatopathology8010007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8008319/
https://www.ncbi.nlm.nih.gov/pubmed/33668724
http://dx.doi.org/10.3390/dermatopathology8010007

Ejemplares similares